Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo
Xun Wang, … , Alan R. Tall, Daniel J. Rader
Xun Wang, … , Alan R. Tall, Daniel J. Rader
Published August 1, 2007
Citation Information: J Clin Invest. 2007;117(8):2216-2224. https://doi.org/10.1172/JCI32057.
View: Text | PDF
Research Article Cardiology

Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo

  • Text
  • PDF
Abstract

Macrophage ATP-binding cassette transporter A1 (ABCA1), scavenger receptor class B type I (SR-BI), and ABCG1 have been shown to promote cholesterol efflux to extracellular acceptors in vitro and influence atherosclerosis in mice, but their roles in mediating reverse cholesterol transport (RCT) from macrophages in vivo are unknown. Using an assay of macrophage RCT in mice, we found that primary macrophages lacking ABCA1 had a significant reduction in macrophage RCT in vivo, demonstrating the importance of ABCA1 in promoting macrophage RCT, however substantial residual RCT exists in the absence of macrophage ABCA1. Using primary macrophages deficient in SR-BI expression, we found that macrophage SR-BI, which was shown to promote cholesterol efflux in vitro, does not contribute to macrophage RCT in vivo. To investigate whether macrophage ABCG1 is involved in macrophage RCT in vivo, we used ABCG1-overexpressing, -knockdown, and -knockout macrophages. We show that increased macrophage ABCG1 expression significantly promoted while knockdown or knockout of macrophage ABCG1 expression significantly reduced macrophage RCT in vivo. Finally, we show that there was a greater decrease in macrophage RCT from cells where both ABCA1 and ABCG1 expression were knocked down than from ABCG1-knockdown cells. These results demonstrate that ABCA1 and ABCG1, but not SR-BI, promote macrophage RCT in vivo and are additive in their effects.

Authors

Xun Wang, Heidi L. Collins, Mollie Ranalletta, Ilia V. Fuki, Jeffrey T. Billheimer, George H. Rothblat, Alan R. Tall, Daniel J. Rader

×

Figure 3

Overexpression of ABCG1 in J774 macrophages promotes cholesterol efflux in vitro and RCT in vivo.

Options: View larger image (or click on image) Download as PowerPoint
Overexpression of ABCG1 in J774 macrophages promotes cholesterol efflux ...
(A) Quantitative analysis of mRNA expression of abcg1 in ABCG1-OE and control cells by quantitative RT-PCR. Total RNA was extracted from cells that were treated with either vehicle or GW3965 (1 μM) for 24 hours. Data are expressed as fold change ± SD and normalized to mouse 18S rRNA. **P < 0.01; ***P < 0.001. (B) Western blot demonstrating the overexpression of ABCG1. Control and ABCG1-OE cells were grown in either the absence or presence of GW3965 as indicated. ABCG1 was detected by Western blotting with anti-ABCG1 antibody. Equal amount of total proteins were loaded. Lanes 1 and 3 represent control cells. Lanes 2 and 4 represent ABCG1-OE cells. (C) Cholesterol efflux assay was performed as described in Figure 1. Cholesterol efflux was determined in the presence of HDL3 (25 μg/ml) or 2.5% mouse whole serum for 4 hours. Data are expressed as mean ± SD; n = 3. *P < 0.05; **P < 0.01. (D and E) The RCT experiment was done as described in Figure 1 with [3H]cholesterol-labeled, acLDL-loaded, and LXR agonist–treated J774 control macrophages and ABCG1-OE macrophages. n = 8 mice per group. Data are expressed as the percentage of tracer relative to total cpm tracer injected ± SEM. **P < 0.01; ***P < 0.001. (D) Time course of [3H]cholesterol distribution in plasma. Individual time points and areas under the curve were determined and compared. (E) Fecal [3H]tracer levels. Feces were collected continuously from 0 to 48 hours.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts